IMMUNIC INC IMUX 深 滬
等待開盤 07-18 09:30:00 美东时间
0.93
+0.034
+3.82%
華盛通- 最 高0.979
- 今 開0.895
- 成交量 129.30万股
- 最 低 0.8929
- 昨 收 0.8958
- 總市值 8911.03万
- 52周最高 2.11
- 市盈率 靜 --
- 換手率 1.35%
- 52周最低 0.561
- 委 比 80.82%
- 總股本 9581.75万
- 歷史最高 28.99
- 量 比 2.01
- 振 幅 9.61%
- 歷史最低 0.561
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunic Reports 92% of MS Patients Had No Disability Worsening After 3 Years on Lead Oral Drug
Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new
06-24 18:36
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $10 price target.
06-05 19:44
Immunic Completes Enrollment For Both Phase 3 ENSURE Trials Of Vidofludimus Calcium In Relapsing Multiple Sclerosis; Top-Line Data Expected End Of 2026
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 –– Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple
06-05 18:33
快讯 | Immunic Inc：Leerink Partners将目标价从6美元削减至4美元
Immunic Inc : Leerink Partners Cuts Target Price to $4 From $6
06-03 18:03
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Immunic Raises $65M in Public Offering, Could Gain $130M More From Warrant Exercises
Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
05-29 19:13
Immunic shares are trading lower after the company announced a proposed public offering.
Immunic shares are trading lower after the company announced a proposed public ...
05-29 04:14
Immunic Announces Proposed Public Offering; No Size Or Amount Disclosed
Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
05-29 04:04
Immunic, Inc. Announces Proposed Public Offering
NEW YORK, May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecul...
05-29 04:02
